Need to Know: Why Coke, others, may be spared, as a $100 billion opportunity in weight loss drugs unfolds says JPMorgan

JPMorgan says the weight-loss drug industry is now a “$100 billion plus opportunity.” Coke is one of the stocks they say is likely to get hit less hard.

Previous post Europe Markets: Barclays drags down U.K. bank stocks after warning on net interest margins
Next post Earnings Results: Verizon logs earnings beat while boosting target on a key metric